-
1.发明公开公开(公告)号：US20240358837A1
公开(公告)日：2024-10-31
申请号：US18692813
申请日：2022-09-16
发明人： Huang-Chiao Huang , Collin Inglut
CPC分类号： A61K41/0071 , A61K9/16 , A61K9/1688 , A61P35/00
摘要： Amorphous nanoparticle compositions comprising a photosensitizer along with methods of making and using the same are provided. In particular, the amorphous nanoparticle compositions are generated and used in carrier-free, solubilizing agent-free applications to improve the photophysical and photochemical stability of clinically used photosensitizers, particularly verteporfin. The amorphous nanoparticle compositions may be used in fluorescence-guided surgery, photodynamic therapy of cancer and non-cancer diseases, fluorescence diagnosis of cancer and non-cancer diseases, blood-brain barrier opening, drug delivery to the brain, and/or in various other types of treatments and implementations.
-
公开(公告)号：US20240350565A1
公开(公告)日：2024-10-24
申请号：US18683538
申请日：2022-08-18
发明人： KATJA JOHNSON , JALIL BENYACOUB
IPC分类号： A61K35/745 , A61K9/16 , C12N1/20
CPC分类号： A61K35/745 , A61K9/16 , C12N1/20
摘要： The present invention provides use of a Bifidobacterium lactis supernatant as a bifidogenic factor. The present invention also provides a Bifidobacterium lactis supernatant for use in enhancing the growth of bifidobacteria in the gastrointestinal tract of a subject. The present invention also provides a Bifidobacterium lactis supernatant for use in treating or preventing a gastrointestinal disease by enhancing the growth of bifidobacteria in the gastrointestinal tract of a subject.
-
公开(公告)号：US20240342222A1
公开(公告)日：2024-10-17
申请号：US18583572
申请日：2024-02-21
IPC分类号： A61K35/37 , A61K9/00 , A61K9/16 , A61K35/00 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26
CPC分类号： A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/30
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US12090128B2
公开(公告)日：2024-09-17
申请号：US18429056
申请日：2024-01-31
发明人： Kristin Patterson , Jiping Liu
IPC分类号： A61K31/167 , A61K9/00 , A61K9/16 , A61K9/20
CPC分类号： A61K31/167 , A61K9/0056 , A61K9/16 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2072
摘要： The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
-
公开(公告)号：US20240216307A1
公开(公告)日：2024-07-04
申请号：US18429056
申请日：2024-01-31
发明人： Kristin PATTERSON , Jiping LIU
IPC分类号： A61K31/167 , A61K9/00 , A61K9/16 , A61K9/20
CPC分类号： A61K31/167 , A61K9/0056 , A61K9/16 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2072
摘要： The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
-
公开(公告)号：US20240207259A1
公开(公告)日：2024-06-27
申请号：US18596349
申请日：2024-03-05
发明人： Peng LI , Robert DAVIS
IPC分类号： A61K31/4985 , A61K9/00 , A61K9/16 , A61K9/48
CPC分类号： A61K31/4985 , A61K9/0053 , A61K9/16 , A61K9/4825 , A61K9/485 , A61K9/4858 , A61K9/4891
摘要： The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
-
公开(公告)号：US11999804B2
公开(公告)日：2024-06-04
申请号：US16729017
申请日：2019-12-27
发明人： Kentaro Nakamura , Tsukasa Kitahashi , Rie Hando , Satoshi Gojo , Daisuke Kami
CPC分类号： C07K7/06 , A61K35/28 , A61K35/33 , A61P43/00 , C12N5/0068 , A61K9/16 , A61K38/00 , C12N2533/40
摘要： An object of the present invention is to provide an excellent treatment agent for a lysosomal storage disease. According to the present invention, there is provided a treatment agent for a lysosomal storage disease including a cell structure which includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type and in which at least one of the polymer blocks is disposed in gaps between the plurality of cells.
-
8.发明公开公开(公告)号：US20240165167A1
公开(公告)日：2024-05-23
申请号：US18428238
申请日：2024-01-31
申请人： AOBIOME LLC
CPC分类号： A61K35/74 , A61K9/0014 , A61K9/0031 , A61K9/0043 , A61K9/0073 , A61K9/08 , A61K9/16 , A61K9/50 , A61K45/06
摘要： Methods of treating neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof by administering ammonia oxidizing microorganisms are disclosed. Preparations for treating disorders, including neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof including ammonia oxidizing microorganisms are disclosed. Kits including ammonia oxidizing microorganism preparations and devices for administering ammonia oxidizing preparations are provided.
-
公开(公告)号：US20240165111A1
公开(公告)日：2024-05-23
申请号：US18502460
申请日：2023-11-06
发明人： Wei YAO , Peng LI , Robert DAVIS , Sharon MATES , Kimberly VANOVER , Gretchen SNYDER
IPC分类号： A61K31/4985 , A61K9/00 , A61K9/16 , A61K31/445 , A61K45/00 , A61K45/06 , A61P25/00 , C07D241/40 , C07D471/16
CPC分类号： A61K31/4985 , A61K9/0019 , A61K9/16 , A61K31/445 , A61K45/00 , A61K45/06 , A61P25/00 , C07D241/40 , C07D471/16
摘要： The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine Di and D2 receptor signaling system, and/or the wopioid receptor.
-
公开(公告)号：US20240123367A1
公开(公告)日：2024-04-18
申请号：US18097352
申请日：2023-01-16
申请人： Velico Medical, Inc.
摘要： The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).
-
-
-
-
-
-
-
-
-
搜索结果
1367 条记录 (耗时 0.171 秒)
